128 results about "INTESTINAL CARCINOMA" patented technology

The present invention discloses CRISPR / Cas9 targeted knockout human intestinal cancer cell RITA gene and specific sgRNA thereof. First, sgRNA specifically targeted to a second exon of the RITA gene isobtained, and the base sequence of the sgRNA is as shown in SEQ ID NO. 1; secondly, a sgRNA lentiviral vector system of the RITA gene is constructed, and the sgRNA lentiviral vector system contains Cas9 protein; and finally human intestinal cancer HT-29 cells are infected with CRISPR / Cas9 lentivirus containing the sgRNA to obtain a cell line which is significantly reduced in RITA protein expression level. The invention has the advantages of simple operation steps, good sgRNA targeting property, and high RITA gene cutting efficiency; furthermore, the constructed CRISPR / Cas9 lentivirus system has the advantage of high knock-out efficiency and can specifically knock out the RITA gene to obtain RITA gene-knockout human intestinal cancer cells, and a powerful tool for the further study of theaction mechanism of RITA in the intestinal cancer cells is provided.

The invention discloses a CRISPR-Cas9 for targeting knockout of a human intestinal cancer cell CNR1 gene, and specific sgRNA sequences thereof. Firstly, an sgRNA specifically targeting CNR1 gene second exon is obtained, and base sequences of the sgRNA are as shown in SEQ ID NO. 1; secondly, the sgRNA of the CNR1 gene is constructed to a lentiviral vector system, and the lentiviral vector system contains Cas9 protein; and finally, a CRISPR / Cas9 lentivirus containing the sgRNA is infected with human intestinal cancer HT-29 cells, and a cell strain with CNR1 protein expression level significantlybeing reduced is obtained. The operation steps are simple, good sgRNA targeting is achieved, and the cutting efficiency to the CNR1 gene is high; and in addition, the constructed CRISPR / Cas9 lentiviral system has the advantage of high knockout efficiency, and can specifically knock out the CNR1 gene, human intestinal cancer cells with the CNR1 gene being knocked out is obtained, and therefore a powerful tool for further study of the mechanism of action of CNR1 in intestinal cancer cells is provided.

The present invention provides a paris total saponin extract for resisting tumor metastasis and a pharmaceutical preparation thereof. The pharmaceutical preparation is composed of paris total saponin extract as the active component and medicinal auxiliary materials; wherein, the weight percentage of paris total saponin extract in the total weight of the pharmaceutical preparation is 60 to 98 percent. The paris total saponin extract for resisting tumor metastasis and the pharmaceutical preparation provided by the present invention have good inhabitation on the metastasis of animal transplanted tumor cells, demonstrated in (1) significant anti-metastasis function for inbred mice and nude mice metastasis model of vaccinated mouse lung adenocarcinoma, human lung cancer, human gastric cancer, human intestinal cancer, human liver cancer and other tumor strains; (2) significant effect on relative albumen metastasis; (3) significant effect on relative gene metastasis and no obvious toxicity on major viscera. In addition, the main active component of the pharmaceutical preparation is a Chinese medicine extract, so compared with chemical drugs, the present invention has the advantage of small toxicity.

The invention provides an application of mitoxantrone and salt thereof as a lymph tracer (such as hydrochloric acid mitoxantrone, oxalic acid mitoxantrone, sulfuric acid mitoxantrone, phosphoric acid mitoxantrone, acetic acid mitoxantrone, citric acid mitoxantrone and the like). The mitoxantrone and salt thereof can be used for preparing injection, powder injection, emulsion, liposome, nanoparticle, microballoon and the like. The mitoxantrone and salt thereof not only can be used for killing malignant tumor cells, but also the blue dye feature can be used as the lymph tracer applied to lymphadenectomy in cancer operative treatment, which is suitable for treating stomach cancer, breast cancer, intestinal cancer, cervical carcinoma, testis cancer and the like.

Methods for treating a patient suffering from a neoplastic disease are disclosed and described. A number of diseases can be treated under the present methods, including without limitation gall bladder cancer, hepato cellular cancer, ovarian cancer, small intestine cancer, lung cancer, mesothelioma, breast cancer, kidney cancer, pancreas cancer, prostate cancer, carcinoid cancer, leiomyosarcoma, or metastasis thereof. A general method for providing such treatment may include: 1) identifying in a patient one or more sentinel and / or metinel lymph nodes draining the neoplasm; 2) resecting the one or more nodes and, optionally all or part of the tumour or metastasis; 3) isolating tumour-reactive T-lymphocytes from said lymph nodes; 4) in vitro expanding said tumour-reactive T-lymphocytes; and 5) administering the thus obtained tumour-reactive T-lymphocytes to the patient.

Methods for treating a patient suffering from a neoplastic disease are disclosed and described. A number of diseases can be treated under the present methods, including without limitation gall bladder cancer, hepato cellular cancer, ovarian cancer, small intestine cancer, lung cancer, mesothelioma, breast cancer, kidney cancer, pancreas cancer, prostate cancer, carcinoid cancer, leiomyosarcoma, or metastasis thereof. A general method for providing such treatment may include: 1) identifying in a patient one or more sentinel and / or metinel lymph nodes draining the neoplasm; 2) resecting the one or more nodes and, optionally all or part of the tumour or metastasis; 3) isolating tumour-reactive T-lymphocytes from said lymph nodes; 4) in vitro expanding said tumour-reactive T-lymphocytes; and 5) administering the thus obtained tumour-reactive T-lymphocytes to the patient.

The invention discloses the novel application of clostridium butyricum to drugs, in particular to the application of the clostridium butyricum to the preparation of a drug combination used for preventing and treating intestinal cancer. The novel application comprises the prevention of chronic intestinal disease canceration such as intestinal polyp, Crohn disease, ulcerative colitis, etc., the adjuvant therapy on advanced inoperable intestinal cancer, the adjuvant therapy after the intestinal cancer operation, etc.; the clostridium butyricum is selected from (but is not limited to) clostridium butyricum, CGMCC, and storage serial number 0313.1. In the forms of live bacteria and pharmic receivable different carriers, the clostridium butyricum is made into tablets, capsules, powders, liquid preparations, suppositories, and enemas; the clostridium butyricum can be used for preventing and treating the intestinal cancer for a long time through the methods of oral administration, clysis, injection in the tumor tissue; therefore, the life of a patient suffering from the intestinal cancer is prolonged, and the life quality of the patient suffering from the intestinal cancer is increased.

The invention discloses a medicine for treating gastrointestinal diseases by utilizing biological live bacteria, which is prepared from the following substances: 1 to 6 weight portions of oligoisomaltose, 1 to 6 weight portions of glucose, as well as 1 to 10 hundred million CFU / gram of bifidobacteria, 1 to 10 hundred million CFU / gram of lactobacilli and 1 to 10 hundred million CFU / gram of probiotics which take the total weight of the oligoisomaltose and the glucose as a radix number, wherein the probiotics are at least one of bacillus, lactococcus and enterococcus. The medicine is based on a modern microecology theory, adopts a probiotic live bacteria preparation to treat diseases such as gastritis, gastric ulcer, enteritis, diarrhea, constipation, indigestion, abdominal distension, diarrhea, intestinal cancer, acute and chronic hepatitis, low immunity and the like, and has the advantages of reliable action, broad function, safe use, no any toxic side effect and irritation, convenient administration and carrying and the like.

The invention provides an anticancer traditional Chinese medicine composition, belonging to the technical field of medicines. The traditional Chinese medicine composition comprises bezoar, sweet wormwood herb, musk, root of China creeper and all-grass of nerved twayblade. The traditional Chinese medicine composition has the beneficial effects that through a reasonable ratio of the five medicinal raw materials, the traditional Chinese medicine composition has synergetic effects and the double effects of directly inhibiting cancer cell growth and proliferation and enhancing the immune function; through clinical research trials, the traditional Chinese medicine composition can selectively inhibit and kill cancer cell proliferation to achieve the anticancer effect, can also promote differentiation of T and B lymphocytes and activate NK cells to enhance the body immunity, has quick treatment effects on cancers, does not have toxic or side effect, has a wide anticancer spectrum, especially has obvious curative effects on lung cancers, liver cancers, gastric cancers, intestinal cancers, lymph cancers, brain tumors, nasopharynx cancers, esophagus cancers, pancreatic cancers and cervical cancers, and does not have any impact on body cells, tissues, organ functions and hemogram in the medication period.

The invention relates to a nucleic acid aptamer for identifying an intestinal cancer serum marker and a preparation method and application of the nucleic acid aptamer. The invention specifically discloses nucleotide sequences of four nucleic acid aptamers and a screening method thereof. First, serum samples of firstly diagnosed patients with intestinal cancer and healthy people are collected, primers and ssDNA of a primary library are synthesized, and magnetic agarose microspheres coupled with carboxyl on the surface are used as a serum protein adsorption carrier, and a subtractive SELEX technology and a real-time fluorescence PCR technology are used to obtain gradually enriched nucleic acid aptamer sequences which specifically bind to intestinal cancer serum proteins. Four aptamers for specifically identifying intestinal cancer serum are screened by high throughput sequencing and data analysis. The four nucleic acid aptamers provided by the invention have the characteristics of high affinity and strong specificity for the serum of patients with intestinal cancer, and have wide application prospects in the aspects of research on intestinal cancer tumor marker fishing, initial screening of patients with intestinal cancer and intestinal cancer targeted drug treatment.

The invention relates to a method for preparing fine dioscin and an application of the fine dioscin to antitumor aspect. The preparation method comprises the following steps of: weighing medicinal materials, putting into an extracting tank, soaking the medicinal materials with a water-containing organic solvent of which the amount is 3-12 times (v / w) that of the medicinal materials for 30-100 minutes, heating to 40-100 DEG C, refluxing or extracting with other auxiliary methods for 1-8 hours, draining an extracting solution, and extracting for 2-5 times; concentrating and recovering the solvent, draining a residual liquid, standing, precipitating a precipitate out, filtering, and drying and smashing a filter cake to obtain a crude product; and repeatedly crystalizing the crude product with the solvent to obtain a pure product of which the purity is over 95 percent. As proved by results of in-vitro and in-vivo antitumor tests on the fine dioscin, the fine dioscin prepared with the method has an antitumor effect, and particularly has better effects on the aspect of inhibition of human intestinal cancers, human kidney cancers, human prostatic cancers and human mammary cancer tumor cells. The fine dioscin prepared with the method can be prepared into antitumor tablets, capsules, injections, oral liquids and the like.

The invention discloses primer group information of fusobacterium nucleatum, a quantitative PCR (Polymerase Chain Reaction) detection method and application of primer group and method. According to a16S rRNA (ribosomal Ribonucleic Acid) nucleotide sequence and a BLAST (Basic Local Alignment Search Tool) function of bacteria in an NCBI (National Center of Biotechnology Information) database, a fusobacterium nucleatum related primer and V3 to V4 primers are designed according to primer design software Primer Primer 5, and the primers are identified. Genome information of total bacteria is extracted from an excrement sample; the qPCR (quantitative Polymerase Chain Reaction) is carried out through utilizing the primers and the relative content of the fusobacterium nucleatum is calculated andobtained. The detection method is used as a principle and an intestinal micro-ecological detection kit is prepared by utilizing the fusobacterium nucleatum primer. A kit is used for carrying out actual detection and a result shows that the content of the fusobacterium nucleatum in the excrement samples of an intestinal micro-ecological patient and a patient with intestinal cancer is remarkably different from that of normal people. A specific primer of the fusobacterium nucleatum, a rapid and accurate detection method and research and development of an intestinal micro-ecological kit provide methods for knowing the distribution of an intestinal micro-ecology and predicating and primarily screening diseases.

The present invention discloses an in-vitro constructed method for accurately predicting medication of patients with cancers. The method comprises the following steps of: 1) constructing an intestinalcancer organoid, namely culturing a purer intestinal cancer organoid by using cancer tissues obtained by operations or biopsies of patients with colon cancer, patients with rectal cancers or patientswith colorectal cancers; and 2) carrying out a large-flux drug screening test and carrying out a high-flux drug sensitivity detection by taking a micro organ as a unit. The in-vitro constructed method for accurately predicting the medication of the patients with the cancers has advantages that grinding the tissues enables digestion time to be shortened and a digestion degree is also consistent; mild digestive juice reduces damages of the step to cells; different pore diameters are used for filtering to screen the required cells more accurately; immune cells are removed to obtain purer cancercells; a self-made culture medium better conforms to components required by growth of intestinal cancer organs and a culture success rate is increased; and medicine screening is carried out by takingthe organoid as a unit, so that responses of the cancer tissues in vivo after clinical medication are better simulated.

The invention discloses a manufacturing method for a straw mushroom dietary fiber beverage, belonging to the field of beverage processing. The manufacturing method is characterized by adopting processing process flow which comprises the following procedures: (1) preparation of stock solutions: a procedure of preparing a stock solution A by subjecting straw mushroom stems to choosing and cleaning, precooking, beating and coarse filtration, preparing a stock solution B by subjecting wolfberry to impurity removal and soaking, crushing, water extraction and coarse filtration and preparing a stock solution C by subjecting carrot to washing and peeling, softening, beating and coarse filtration; and (2) preparation of a finished product: a procedure of subjecting the stock solution A, the stock solution B and the stock solution C to blending, degassing, homogenization and sterilization so as to obtain the finished product. The invention has the following beneficial effects: the prepared straw mushroom dietary fiber beverage has an orange color, composite flavor unique to straw mushroom, carrot and wolfberry, slippery and smooth mouthfeel and agreeable sour-sweet taste; the prepared straw mushroom dietary fiber beverage has abundant nutrients and a great amount of dietary fiber, can promote gastrointestinal motility and effectively prevent intestinal cancer, gastrointestinal carcinoma, hemorrhoid and the like and is capable of improving human immunity.

The invention provides an anti-virus or / and anti-tumor drug and a preparation method thereof and an application of fenugreek biflavone glycosides for preparing anti-virus or / and anti-tumor drugs. The invention provides the application of the chemical component fenugreek biflavone glycosides in fenugreek seeds as drugs for the first time, and uses the fenugreek biflavone glycosides for preparing anti-virus drugs and anti-tumor drugs for the first time. In vivo and in vitro experiment research shows that fenugreek biflavone glycoside tablets or fenugreek biflavone glycoside capsules of the invention have obvious effect on resisting influenza viruses, and the anti-influenza drug effect of the fenugreek biflavone glycoside tablets or fenugreek biflavone glycoside capsules of the invention is superior to the anti-influenza drug effect of the existing Western medicine ribavirin tablets. The anti-HBV effect of the fenugreek biflavone glycoside tablets or fenugreek biflavone glycoside capsules is superior to the anti-HBV effect of kurarinone capsules, and the anti-HIV effect of the fenugreek biflavone glycoside tablets or fenugreek biflavone glycoside capsules is superior to the anti-HIV effect of zidovudine tablets. The fenugreek biflavone glycoside tablets or fenugreek biflavone glycoside capsules have obvious effect on resisting proliferation of liver cancer, gastric cancer, intestinal cancer, lung cancer and cervical cancer cells, and the anti-tumor effect of the fenugreek biflavone glycoside tablets or fenugreek biflavone glycoside capsules is superior to the anti-tumor effect of the existing chemical component preparation hydroxycamptothecine injection.

The invention relates to a humanized intestinal cancer precancerous lesion immortalized epithelial cell line and a construction method and application thereof. The construction method comprises the following steps: firstly, transfecting primarily separated human colorectal adenoma polyp epithelial cells by using an SV40 overexpression lentiviral vector, then performing screening by using puromycin, and finally amplifying the screened cells to obtain the humanized intestinal cancer precancerous lesion immortalized epithelial cell line. The humanized intestinal cancer precancerous lesion immortalized epithelial cell line constructed by the invention overcomes the problems that conventional adenoma polyp cannot be subjected to passage in vitro, is low in cell proliferation and poor in cell activity, and cannot meet the cell passage requirement. According to the invention, the humanized intestinal cancer precancerous lesion immortalized epithelial cell line is established for the first time, an important cell experiment tool is provided for developing an in-vitro experiment of intestinal cancer precancerous lesions, and preclinical researches such as new drug screening and drug effectcomponents are also convenient to develop.

The invention discloses a polypeptide to specifically promote degradation of EGFR (epidermal growth factor receptor) protein, or its derivatives, and application of the polypeptide in the preparationof tumor drugs. An amino acid sequence of the polypeptide is shown as in sequence table SEQ ID No. 1; alternatively, two or more amino acids in the amino acid sequence shown as in the sequence table SEQ ID No. 1 are replaced with side-chain-connectable non-natural amino acids; the derivatives include chimeric peptides that are formed by connecting the polypeptide with cell penetrating peptides. The polypeptide or its derivatives can promote degradation of EGFR protein and inhibit EGFR signal pathway activity; therefore, the polypeptide or its derivatives are applicable to the preparation of tumor drugs. Drugs prepared herein are suitable for treating the tumors, such as lung cancer, intestinal cancer, pancreatic cancer, breast cancer, liver cancer, and glioma.

Elevated levels of cathepsin E (catE) are demonstrated to be diagnostic of intestinal forms of cancer, such as colorectal cancer. Elevated levels of cathepsin E (catE, monomeric forms) are demonstrated to be detectable in the urine of animals having colorectal cancer, and a diagnostic / screening method for identifying and / or detecting colorectal cancer in an animal from a urine sample is provided. Specific tissue immunohistochemcial staining for catE (monomeric forms) in dysplastic tissue is also disclosed, and is shown to correlate with the level of dysplastic lesion severity. Hence, a method for identifying and determining the level of dysplastic lesion severity is provided. Cathepsin E mRNA transcription and expression levels are also demonstrated to be upregulated in dysplastic tissue, relative to non-dysplastic tissue. Hence, a method for transcriptionally profiling an animal to monitor the progression of colorectal disease is provided.

A method for configuring the eucaryotic expression carrier of cell factor IL-24 includes designing the ascending and descending primers, PCR amplifying begining from the second amino acid in the code at human IL-24 N terminal by using TRAPIL-24 plasmid as template, cutting off target band, purifying it with reagent kit, configuring and determining recombinant plasmid pEGFP-CI-IL-24, respectively enzyme-severing the PCR product and carrier pEGFP by Bgl II and Sal I, purifying them by reagent kit, linking fragment, culturing, cloning, determining and sequencing. The recombinant cell factor Il-24 can be used to treat liver cancer, small intestine cancer and melanoma.

The invention relates to a traditional Chinese medicine with special anti-cancer effect for the treatment of adenocarcinoma classified by cytology, which is prepared by the traditional Chinese medicine raw materials with the weight percentage: 14 percent of ginseng, 13 percent of sanchi, 13 percent of prepared turtle shell, 1 percent of artificial musk, 13 percent of prepared turtle shell, 13 percent of adulterated pangolin scales, 15 percent of Chinese eaglewood, 13 percent of herba violae, 1 percent of gamboge and 4 percent of toad skin; the traditional Chinese medicine raw materials are ground into traditional Chinese medicine powder; the traditional Chinese medicine has the effects of strengthening body resistance, strengthening vital qi to eliminate pathogenic factor, nourishing yin, suppressing hyperactive yang, clearing heat, removing toxin, softening, resolving hard mass, activating blood circulation, removing blood stasis, enhancing human immunity, having vitality to kill cancer cells and having no evident toxicity to normal cells, thus being used for the treatment of adenocarcinoma, carcinoma of stomach, intestinal carcinoma, breast carcinoma, liver carcinoma and peripheral pulmonary carcinoma.

The invention relates to a pharmaceutical composition containing an insulin-like growth factor-I receptor inhibitor and a histon deacetylase (HDAC) inhibitor and an application thereof in preparing medicines for treating intestinal cancer, liver cancer, lung cancer, kidney cancer, gastric cancer, brain tumor, sarcoma, pancreatic cancer, ovarian cancer, breast cancer or prostate cancer. The pharmaceutical composition of the invention has obvious synergistic effect, thus improving curative effect of medicines, lowering administration dosage and reducing occurrence of side effect.

The invention provides an application of a composition of a clostridium butyricum and bifidobacterium dual live bacteria preparation and an anticancer medicament in preparation of a medicament for treating intestinal cancer. The aim of treating the intestinal cancer is fulfilled by combining the anticancer medicament and the clostridium butyricum and bifidobacterium dual live bacteria preparation; and the composition of the clostridium butyricum and bifidobacterium dual live bacteria preparation and the anticancer medicament has an effective effect of treating the intestinal cancer, so that the lives of intestinal cancer patients are prolonged, and the living quality of the intestinal cancer patients is improved.

The invention relates to a novel bisamides derivative and a preparation method and an application thereof. A general formula of the novel bisamides derivative is shown as follows, and each group is shown in patent claims. The novel bisamides derivative has good antineoplastic activity, such as lung cancer, liver cancer and intestinal cancer. partial compound has higher in-vitro inhibition rate on three cancer cell bacterial strains than a control sample 5-fluorouracil, partial compound has in-vitro inhibition rate on lung adenocarcinoma (A549), liver cancer(Bel7402) and intestinal cancer (HCT-8) three cancer cell bacterial strains as high as more than 85%, and most compound has in-vitro inhibition rate on liver cancer (Bel7402) cell bacterial strain as high as more than 80%. The novel bisamides derivative can possibly be an antitumor drug.

Multi-phase and single-phase chemical reaction schemes have been developed for the synthesis of pharmaceutical-ligand analogs, pharmaceutical-pharmaceutical analogs, and similar molecular-molecular analogs that possess multiple mechanisms of action. The multi-phase organic chemical reaction schemes include relatively mild reaction conditions, high end product yields, and comparatively rapid completion of chemical reactions, which are all of particular utility for the synthesis of preparations including covalent pharmaceutical-receptor ligand or pharmaceutical-immunoglobulin analogs. Examples of pharmaceutical-ligand preparations that can be synthesized utilizing the multi-step chemical reaction schemes include covalent chemotherapeutic-ligand agents that possess selective targeted delivery properties and a capacity to exert additive and synergistic levels of cytotoxic anti-neoplastic potency. Pharmaceutical-pharmaceutical analogs, including chemotherapeutic-chemotherapeutic analogs that are capable of exerting multiple mechanisms of action, can be synthesized using either of the described multi-phase or single-phase organic chemistry reaction schemes. Each of these representative examples has utility against a spectrum of disease states including, for example, neoplastic conditions such as mammary adenocarcinoma / carcinoma, ovarian carcinoma, prostatic carcinoma, intestinal carcinoma, melanoma, leukemia, myeloma, and lymphoma.

The invention belongs to the technical field of medical detection application and discloses a method for detecting cytokines secreted by specific T cells in lung cancer or intestinal cancer. A systemis composed of a detection sample, a target, a stimulation antigens and / or positive control antigens of the detection sample and conventional reagents of the detection sample. The sample in the detection system is mononuclear cells after peripheral blood of a lung cancer or intestinal cancer patient is separated, and cytokines secreted by the specific T cells are detected through a plurality of rounds of stimulation of polypeptide. According to the method, the mononuclear cells are induced into DC cells; the DC cells and the T cells are co-cultured; after the polypeptide is added and three rounds of stimulation is carried out, the cytokines secreted by the specific T cells are detected; and under the condition that detection sensitivity is not influenced, detection time of the whole systemis reduced. According to the detection system provided by the invention, an application method is simple, rapid and efficient. The detection time is reduced. Detection efficiency is improved. The detection system provided by the invention is wide in application range and has huge market value.

The invention discloses a standardized culture medium for three-dimensional culture of intestinal and intestinal cancer tissue organs and a culture method. The standardized culture medium comprises atleast one or more of a reagent A, a reagent B and a reagent C; wherein the reagent A comprises one or more of Nacetylcysteine, Y-27632, A8301, a recombinant human epidermal growth factor and gastrin;and the reagent B is prepared from one or more of R-spodin1, Noggin, nicotinamide and SB202190, and the reagent C comprises Wnt-3A. According to the culture medium disclosed by the invention, aimingat the growth characteristics of adult stem cells in intestinal tissues, various growth factor components are selected for blending, and by optimizing the proportion of growth factors in the culture medium, the adult stem cells of intestines and cells of intestinal cancer can effectively form organoids of intestines and organoids of intestinal cancer respectively in a three-dimensional culture environment.

The invention belongs to the technical field of nanometer functional materials, immunization analysis and biosensing and provides a preparation method and use of a Pd / V2O5 / MWCNTs-based intestinal cancer tumor marker immunosensor. Through use of Pd / V2O5 / MWCNTs as a detection antibody marker, a sandwiched electrochemical immunosensor for detecting an intestinal cancer tumor marker is prepared. Through excellent biocompatibility and high catalytic performances of Pd / V2O5 / MWCNTs, the immunosensor has the advantages of high specificity, high sensitivity and low detecting limit.

The invention provides a benzyloxy aromatic ring structure compound represented by a general formula (I), a stereoisomer, an enantiomer or a pharmaceutically acceptable salt thereof, a preparation method thereof, a pharmaceutical composition containing the same, and uses thereof. The compound shown in the general formula (I) can be used for preparing a small-molecule inhibitor of PD1 / PDL1 interaction, and can be used for preventing and / or treating diseases related to PD1 / PDL1 interaction, especially cancers, such as non-small cell lung cancer, small cell lung cancer, melanoma, head and neck cancer, kidney cancer, bladder cancer, local advanced or metastatic urothelial cancer, breast cancer, cervical cancer, metastatic Merkel cell cancer, prostate cancer, liver cancer, intestinal cancer, stomach cancer, multiple myeloma, mantle cell lymphoma, diffuse large B cell lymphoma, liver cancer, hodgkin lymphoma, chronic lymphocytic leukemia, squamous cell carcinoma and the like.

The invention belongs to the field of pharmaceutical chemistry and relates to a 9,10-anthraquinone compound and a pharmaceutical application thereof, in particular to the 9,10-anthraquinone compound and the application thereof in the preparation of a phosphoglycerate mutase inhibitor and in the preparation of drugs for treating cancer. In particular, the invention discloses the application of the9,10-anthraquinone compound shown in the structure of a formula I, pharmaceutically-acceptable salts thereof, or a pharmaceutical composition taking the 9,10-anthraquinone compound as an effective active ingredient in preparing drugs for preventing and treating tumors. The compound can inhibit phosphoglycerate mutase activity and reduce cell metabolism level, and can be used for treating diseasessuch as solid tumors and blood tumors, and the tumors involved are pancreatic cancer, lung cancer, liver cancer, gastric cancer, esophageal cancer, intestinal cancer, breast cancer, cervical cancer, leukemia and melanoma.

The invention provides an application of mitoxantrone and salt thereof as a lymph tracer (such as hydrochloric acid mitoxantrone, oxalic acid mitoxantrone, sulfuric acid mitoxantrone, phosphoric acid mitoxantrone, acetic acid mitoxantrone, citric acid mitoxantrone and the like). The mitoxantrone and salt thereof can be used for preparing injection, powder injection, emulsion, liposome, nanoparticle, microballoon and the like. The mitoxantrone and salt thereof not only can be used for killing malignant tumor cells, but also the blue dye feature can be used as the lymph tracer applied to lymphadenectomy in cancer operative treatment, which is suitable for treating stomach cancer, breast cancer, intestinal cancer, cervical carcinoma, testis cancer and the like.